Bristol Myers Squibb

Abatacept (Orencia) is a biologic medicine that calms overactive immune responses by blocking a key step in T-cell activation. It is used to treat rheumatoid arthritis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and to help prevent acute graft-versus-host disease after stem cell transplant.

Abatacept is an engineered protein that blocks a step needed to fully activate T cells, a type of white blood cell involved in inflammation. Normally,

Sotyktu (deucravacitinib) is a selective TYK2 inhibitor from Bristol-Myers Squibb that blocks one specific kinase in the inflammatory signalling chain, calming the immune overactivity that drives plaque psoriasis and psoriatic arthritis. It is taken by mouth and does not require routine laboratory monitoring for organ toxicity.

Deucravacitinib is a tablet that blocks an enzyme inside immune cells called TYK2. TYK2 carries messages from cytokines — inflammatory chemical signal

Yervoy (ipilimumab) is a CTLA-4 checkpoint inhibitor from Bristol-Myers Squibb. By releasing a key brake on T-cell activation it helped establish cancer immunotherapy, and is used in advanced melanoma, alone or with nivolumab.

T cells are activated in lymph nodes, but a receptor called CTLA-4 naturally limits how strongly they respond. Some cancers take advantage of this bra

Revlimid (lenalidomide) is an oral immunomodulatory drug from Bristol-Myers Squibb. It redirects the cell's protein-degradation machinery against specific cancer-supporting proteins and is a backbone of multiple myeloma therapy, alone or in combination.

Lenalidomide changes how the cell's protein-recycling system works. It binds a protein called cereblon and redirects the machinery to break down certa

Metformin (Glucophage) is an oral biguanide for type 2 diabetes. It lowers blood glucose mainly by reducing glucose output from the liver and by helping the body respond better to its own insulin. It is used with diet and exercise in adults and children aged 10 years and older.

Metformin lowers blood glucose in three main ways. First, it reduces the amount of glucose the liver makes and releases between meals. Second, it decr

Opdivo (nivolumab) is a PD-1 checkpoint inhibitor from Bristol-Myers Squibb used across many cancers, including melanoma, lung, kidney, bladder, liver, esophageal and gastric cancers, and Hodgkin lymphoma. By releasing the PD-1 brake on T cells, it restores immune attack on tumours, alone or with combinations.

T cells are built to destroy abnormal cells, but many cancers protect themselves by displaying ligands PD-L1 and PD-L2, which bind the PD-1 receptor o